

CORRECTION

Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer

The *PLOS ONE* Staff

Notice of republication

This article was republished on April 8, 2021, to correct errors in the Data Availability Statement that were introduced during the typesetting process. The publisher apologizes for the errors. Please download this article again to view the correct version. The originally published, uncorrected article and the republished, corrected articles are provided here for reference.

Supporting information

S1 File. Originally published, uncorrected article.


(PDF)

S2 File. Republished, corrected article.

(PDF)

Reference

1. Frame S, Saladino C, MacKay C, Atrash B, Sheldrake P, McDonald E, et al. (2020) Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. *PLoS ONE* 15(7): e0234103. <https://doi.org/10.1371/journal.pone.0234103> PMID: 32645016



OPEN ACCESS

Citation: The *PLOS ONE* Staff (2021) Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. *PLoS ONE* 16(5): e0251671. <https://doi.org/10.1371/journal.pone.0251671>

Published: May 6, 2021

Copyright: © 2021 The PLOS ONE Staff. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.